FDA Declines to Approve Regeneron's Higher-Dose Eylea
US health regulators on Tuesday declined to approve a higher-dose version of Regeneron's drug Eylea for treatment of a disease that is leading cause of blindness among the elderly.
Reuters Health Information
source https://www.medscape.com/s/viewarticle/993767?src=rss
Reuters Health Information
source https://www.medscape.com/s/viewarticle/993767?src=rss
Comments
Post a Comment